Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Infliximab counteracts tumor necrosis factor-α-enhanced induction of matrix metalloproteinases that degrade claudin and occludin in non-pigmented ciliary epithelium.

Yamada H, Yoneda M, Inaguma S, Watanabe D, Banno S, Yoshikawa K, Mizutani K, Iwaki M, Zako M.

Biochem Pharmacol. 2013 Jun 15;85(12):1770-82. doi: 10.1016/j.bcp.2013.04.006. Epub 2013 Apr 16.

PMID:
23603294
2.

Effect of infliximab on tumor necrosis factor-alpha-induced alterations in retinal microvascular endothelial cells and retinal pigment epithelial cells.

Li H, Yoneda M, Takeyama M, Sugita I, Tsunekawa H, Yamada H, Watanabe D, Mukai T, Yamamura M, Iwaki M, Zako M.

J Ocul Pharmacol Ther. 2010 Dec;26(6):549-56. doi: 10.1089/jop.2010.0079. Epub 2010 Nov 5.

PMID:
21054185
3.

Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease.

Meijer MJ, Mieremet-Ooms MA, van Duijn W, van der Zon AM, Hanemaaijer R, Verheijen JH, van Hogezand RA, Lamers CB, Verspaget HW.

Inflamm Bowel Dis. 2007 Feb;13(2):200-10.

PMID:
17206679
4.

Tumor necrosis factor-α induces matrix metalloproteinases-3, -10, and -13 in human periodontal ligament cells.

Ahn SJ, Rhim EM, Kim JY, Kim KH, Lee HW, Kim EC, Park SH.

J Periodontol. 2014 Mar;85(3):490-7. doi: 10.1902/jop.2013.130063. Epub 2013 May 20.

PMID:
23688099
5.

Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.

Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, Van Den Bosch F, Veys EM, De Keyser F, Baeten D.

Arthritis Rheum. 2004 Sep;50(9):2942-53.

6.

Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases.

Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C.

Carcinogenesis. 2004 Aug;25(8):1543-9. Epub 2004 Mar 25.

PMID:
15044327
7.

MMPs contribute to TNF-alpha-induced alteration of the blood-cerebrospinal fluid barrier in vitro.

Zeni P, Doepker E, Schulze-Topphoff U, Huewel S, Tenenbaum T, Galla HJ.

Am J Physiol Cell Physiol. 2007 Sep;293(3):C855-64. Epub 2007 May 16. Erratum in: Am J Physiol Cell Physiol. 2007 Nov;293(5):C1731. Schulze Topphoff, Ulf [corrected to Schulze-Topphoff, Ulf].

PMID:
17507431
8.

Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover.

Phillips PA, McCarroll JA, Park S, Wu MJ, Pirola R, Korsten M, Wilson JS, Apte MV.

Gut. 2003 Feb;52(2):275-82.

9.

Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat.

Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA.

J Cereb Blood Flow Metab. 2007 Apr;27(4):697-709. Epub 2006 Jul 19.

PMID:
16850029
10.

A Rho-Associated Kinase Inhibitor Protects Permeability in a Cell Culture Model of Ocular Disease, and Reduces Aqueous Flare in Anterior Uveitis.

Yamada H, Yoneda M, Inaguma S, Gosho M, Murasawa Y, Isogai Z, Zako M.

J Ocul Pharmacol Ther. 2017 Apr;33(3):176-185. doi: 10.1089/jop.2016.0085. Epub 2017 Feb 3.

PMID:
28157424
11.

Analysis of alpha2-adrenergic receptors and effect of brimonidine on matrix metalloproteinases and their inhibitors in human ciliary body.

Ooi YH, Oh DJ, Rhee DJ.

Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4237-43. doi: 10.1167/iovs.08-2312. Epub 2009 Mar 25.

PMID:
19324857
12.

Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases.

Yamada H, Yoneda M, Gosho M, Kato T, Zako M.

BMC Ophthalmol. 2016 Mar 8;16:26. doi: 10.1186/s12886-016-0202-8.

13.

Matrix metalloproteinase-9-deficient dendritic cells have impaired migration through tracheal epithelial tight junctions.

Ichiyasu H, McCormack JM, McCarthy KM, Dombkowski D, Preffer FI, Schneeberger EE.

Am J Respir Cell Mol Biol. 2004 Jun;30(6):761-70. Epub 2003 Dec 4.

PMID:
14656746
15.

Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease.

Gao Q, Meijer MJ, Schlüter UG, van Hogezand RA, van der Zon JM, van den Berg M, van Duijn W, Lamers CB, Verspaget HW.

Inflamm Bowel Dis. 2007 Jun;13(6):693-702.

PMID:
17243139
16.

Interleukin-1beta and tumor necrosis factor-alpha have opposite effects on fibroblasts and epithelial cells during basement membrane formation.

Furuyama A, Hosokawa T, Mochitate K.

Matrix Biol. 2008 Jun;27(5):429-40. doi: 10.1016/j.matbio.2008.02.005. Epub 2008 Feb 29.

PMID:
18434122
17.

Regulation of endothelin-1 in human non-pigmented ciliary epithelial cells by tumor necrosis factor-alpha.

Prasanna G, Dibas A, Tao W, White K, Yorio T.

Exp Eye Res. 1998 Jan;66(1):9-18.

PMID:
9533826
18.

Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.

Di Sabatino A, Pender SL, Jackson CL, Prothero JD, Gordon JN, Picariello L, Rovedatti L, Docena G, Monteleone G, Rampton DS, Tonelli F, Corazza GR, MacDonald TT.

Gastroenterology. 2007 Jul;133(1):137-49. Epub 2007 May 5.

PMID:
17631138
19.

Transforming growth factor-beta suppresses tumor necrosis factor alpha-induced matrix metalloproteinase-9 expression in monocytes.

Vaday GG, Schor H, Rahat MA, Lahat N, Lider O.

J Leukoc Biol. 2001 Apr;69(4):613-21.

PMID:
11310848
20.

Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins.

Ishihara H, Kubota H, Lindberg RL, Leppert D, Gloor SM, Errede M, Virgintino D, Fontana A, Yonekawa Y, Frei K.

J Neuropathol Exp Neurol. 2008 May;67(5):435-48. doi: 10.1097/NEN.0b013e31816fd622.

PMID:
18431253

Supplemental Content

Support Center